智飞生物：近日获得美国专利商标局颁发的发明专利证书

Group 1 - The core point of the article is that Zhifei Biological (SZ 300122) announced the acquisition of a patent for a combined vaccine targeting respiratory syncytial virus (RSV) infection, which could enhance its product portfolio and market position [1] - Zhifei Biological's revenue composition for the year 2024 is projected to be 99.14% from biological products and 0.86% from other businesses, indicating a strong focus on its core offerings [1] - As of the report, Zhifei Biological has a market capitalization of 48.7 billion yuan, reflecting its significant presence in the biotechnology sector [1]